Diseases [C] » Neoplasms [C04] » Neoplasms by Site » Breast Neoplasms
Diseases [C] » Skin and Connective Tissue Diseases [C17] » Skin Diseases » Breast Diseases » Breast Neoplasms
Hierarchy View
Subtype Terms (8)
Breast Carcinoma In Situ
12 drugs (11 approved, 1 experimental)
Breast Neoplasms, Male
102 drugs (61 approved, 41 experimental)
Carcinoma, Ductal, Breast
13 drugs (8 approved, 5 experimental)
Carcinoma, Lobular
4 approved drugs
Hereditary Breast and Ovarian Cancer Syndrome
10 drugs (6 approved, 4 experimental)
Inflammatory Breast Neoplasms
45 drugs (36 approved, 9 experimental)
Triple Negative Breast Neoplasms
365 drugs (106 approved, 259 experimental)
Phase 4 Indicated Drugs (94)
Phase 3 Indicated Drugs (215)
acetylsalicylic acid (aspirin)
autologous hematopoietic stem cells
conjugated equine estrogens (Premarin)
corynebacterium granulosum p40
Efbemalenograstim alpha (Ryzneuta)
ferric carboxymaltose (Injectafer)
human choriogonadotropin alfa (hCG)
hyaluronidase (human recombinant) (Hylenex)
interferon alpha-2b (Intron-A)
Phase 2 Indicated Drugs (550)
18 F-Fluoro-5α-Dihydrotestosterone
adenoviral vector expressing hsv-tk
allogeneic gm-csf-secreting breast cancer vaccine
allogeneic hematopoietic stem cells (Hemacord)
allogeneic natural killer cells
anti-egfr immunoliposomes loaded with doxorubicin
antigen pulsed dendritic cells
anti-her2/her3 dendritic cell vaccine
Anti-thymocyte Globulin (Rabbit) (Thymoglobulin)
autologous cytokine induced killer cells
autologous dendritic cells loaded with autologous tumor lysate
bis-choline tetrathiomolybdate
bismuth subsalicylate (Pepto-Bismol)
bivalent oral polio vaccine (bopv), type 1 and type 3 (BOPV)
estrogens, esterified (menrium component estrogens, esterified)
F 18-fluoroazomycin arabinoside (faza)
her2bi-armed activated t cells
hydroxychloroquine (plaquenil)
lutetium dotatate lu-177 (Lutathera)
mirvetuximab soravtansine (Elahere)
modified vaccinia ankara-5t4 vaccine
multi-epitope folate receptor alpha peptide vaccine
multi-valent pneumococcal conjugate vaccine
peripheral blood progenitor cells carrying mdr1
personalized synthetic long peptide vaccine
pumvc3-igfbp2-her2-igf1r plasmid dna vaccine
radiolabeled albumin technetium Tc-99m albumin colloid kit (Microlite)
recombinant adenoviral human p53 gene
silver sulfadiazine (silvadene)
sodium deoxyribonucleate (Derinat)
synthetic tumor-associated peptide vaccine therapy
talimogene laherparepvec (Imlygic)
Tetanus and diphtheria toxoids adsorbed (Decavac)
tumor associated antigen specific cytotoxic t lymphocytes
tumour infiltrating lymphocytes
vaccinia-cea(6d)-tricom vaccine
Phase 1 Indicated Drugs (453)
1-(2-[18f]fluoroethyl)-l-tryptophan
18f-fluorobenzyl triphenyl phosphonium
23-valent pneumococcal polysaccharide vaccine (pneumovax-23)
9 peptides from her-2/neu, cea, & cta
adenoviral vector encoding rat her-2/neu
adenovirus-mediated human interleukin-12
adher-2/neu transduced dendritic cells
ad-sig-hmuc-1/ecdcd40l vaccine
alpha-tocopheryloxyacetic acid
anti-ny eso-1 tcr-transduced t cells
autologous ad her2 dendritic cells
autologous cd19/cd22 chimeric antigen receptor t-cells
autologous, engineered t cells targeting tp53 r175h
hepatitis a vaccine, inactivated (vaqta)
hepatitis b vaccine (recombinant) (Recombivax)
htert/survivin multi-peptide vaccine
in111 monoclonal antibody bre-3
mfe23 scfv-expressing autologous anti-cea mfez t lymphocytes
modified vaccinia virus ankara vaccine expressing p53
mvf-her-2(628-647)-crl 1005 vaccine
ocpm immunotherapeutic vaccine
oncolytic measles virus encoding helicobacter pylori neutrophil-activating protein
oncolytic measles virus encoding thyroidal sodium iodide symporter
oncolytic virus cf33-expressing hnis/anti-pd-l1 antibody
personalized neoantigen vaccine
phentolamine mesylate (regitine)
pneumococcal 13-valent conjugate vaccine (prevnar 13)
ror1 car-specific autologous t-lymphocytes
stimotimagene copolymerplasmid
synthetic breast cancer peptides
telomerase: 540-548 peptide vaccine
tgfbeta resistant her2/ebv-ctls
transferrin receptor-targeted liposomal p53 cdna
tumor blood vessel antigen peptide-pulsed alpha-type-1 polarized dendritic cell
Other Experimental Indicated Drugs (124)
gadofosveset trisodium (ablavar)
globo-h-gm2-lewis-y-muc1-32(aa)-stn(c)-tf(c)-tn(c)-klh conjugate vaccine
htert/survivin/cmv multipeptide vaccine
Organization Involved with Phase 4 Indications (118)
Advanced Medical Services GmbH
Anglo Celtic Cooperative Oncology Group
Arbeitsgemeinschaft fur Internistische Onkologie (AIO)
Canadian Breast Cancer Foundation
Catholic University of Sacred Heart, Rome
Chinese Academy of Medical Sciences
Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie e.V.
First People's Hospital of Hangzhou
German Breast Group Forschungs GmbH
Hospital Universitario Arnau de Vilanova de Lleida
Institut fuer Frauengesundheit
Kidwai Memorial Institute of Oncology, Bangalore
Memorial Health University Medical Center
Morton Plant Mease Health Care
Norwegian University of Science and Technology
Oncologia Medica dell'Ospedale Fatebenefratelli
Scottish Cancer Therapy Network
Shijiazhuang Pharma Group (CSPC)
Spanish Breast Cancer Research Group
Organization Involved with Phase 3 Indications (476)
Academic and Community Cancer Research United
Arbeitskreis Klinische Studien
Association Francaise pour la Recherche Thermale
Australia and New Zealand Breast Cancer Trials Group
Austrian Breast and Colorectal Cancer Group
Bethune International Peace Hospital
BioNumerik Pharmaceuticals, Inc.
Brazilian Breast Cancer Study Group (GBECAM)
Breast Cancer Research Foundation
British Association of Surgical Oncology: Breast Group
British Columbia Cancer Agency
Cancer and Leukemia Group B (CALGB)
Cancer International Research Group
Cancer Research for the Ozarks
Cantonal Hospital of St. Gallen
Case Western Reserve University
Central European Cooperative Oncology Group
Centro di Riferimento Oncologico - Aviano
Centro Hospitalar Lisboa Ocidental
Centro Oncologico de Excelencia
Chao Family Comprehensive Cancer Center
China Breast Cancer Clinical Study Group
China National Biotec Group Co., Ltd
Chinese Anti-Cancer Association
Chinese University of Hong Kong
City of Hope National Medical Center
Clinical Research Technology S.r.l.
Complejo Hospitalario de Especialidades Juan Ramón Jimenez
Complejo Hospitalario Juan Canalejo
Comprehensive Support Project for Oncology Research
Daehwa Pharmaceutical Co., Ltd.
Danish Breast Cancer Cooperative Group
Dharmais National Cancer Center Hospital
Eastern Cooperative Oncology Group
ECOG-ACRIN Cancer Research Group
EddingPharm Oncology Co., LTD.
Facing Our Risk of Cancer Empowered
Fairfax Northern Virginia Hematology Oncology, PC - Fairfax
Fonden Til Fremme af Klinisk- Eksperimentel Cancerforskning
Frontier Science and Technology Research Foundation Inc (FS)
Frontier Science & Technology Research Foundation, Inc.
Gemeinschaftspraxis für Hämatologie und Onkologie
General Drug House Ltd., Bangkok
Generon (Shanghai) Corporation Ltd.
Grupo Oncologico Cooperativo del Sur
Gruppo Italiano Mammella (GIM)
Guangdong Provincial Hospital of Traditional Chinese Medicine
Hellenic Breast Surgeons Society
Hellenic Oncology Research Group
Herbert Irving Comprehensive Cancer Center
Hospital Comarcal de Barbastro
Hospital General de Guadalajara
Hospital Madrid Norte Sanchinarro
Hospital Municipal de Badalona
Hospital Provincial de Córdoba
Hospital Universitario Ntra. Sra. de La Candelaria
Hospital Universitario Puerta del Mar
Hospital Virgen de la Victoria
Huazhong University of Science and Technology
IBEROAMERICAN COALITION FOR BREAST ONCOLOGY RESEARCH
ICO Centre Regional Rene Gauducheau
Indian Council of Medical Research
Institut de Cancérologie de la Loire (ICLN)
Institut de Cancérologie de Lorraine
Institut de Cancerologie de l'Ouest Paul Papin
Institut de Cancérologie Lucien Neuwirth
Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes
International Breast Cancer Research Foundation
International Breast Cancer Study Group
International Cancer Research Group, United Arab Emirates
International Collaborative Cancer Group
Istituto Clinico Humanitas - Rozzano (MI), Italy
Istituto Nazionale per lo Studio e la Cura dei Tumori
Istituto Oncologico della Svizzera Italiana IOSI
Istituto Oncologico Veneto IRCCS
Japan Breast Cancer Research Group
Jiangsu Cancer Institute & Hospital
Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
Jilin Provincial Tumor Hospital
Katholieke Universiteit Leuven
Kyoto Breast Cancer Research Network
Kyoto Prefectural University of Medicine
Lambda Therapeutic Research Ltd
Latin American Cooperative Oncology Group
MacDonald Women's Hospital, Cleveland
MANTA 1 Study Italian Collaborative Group
Maria Sklodowska Curie Children's Hospital
Mastering Breast Cancer Initiative, LLC
Medical Oncology 2, Istituto Oncologico Veneto
National Cancer Institute, France
National Cancer Research Network
Nationale Centrum für Tumorerkrankungen
National Heart, Lung, and Blood Institute (NHLBI)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
National Institute on Aging (NIA)
National Research Council of Thailand
National Shikoku Cancer Center
Neijiang Second People's Hospital
New York Presbyterian Hospital
North Central Cancer Treatment Group
North Eastern Germany Society of Gynaecologic Oncology
Oncocare Sonnenhof-Klinik Engeriedspital
Onkologische Schwerpunktpraxis Eppendorf
Oregon Health and Science University
Osaka Medical Center for Cancer and Cardiovascular Diseases
Ospedale S. Giovanni Bellinzona
People's Liberation Army of China
Pierre and Marie Curie University
Postgraduate Institute of Medical Education and Research
ProHEALTH Care Associates, LLP
QUID Quality in Drugs and Devices Latin American Consulting SRL
Radiation Therapy Oncology Group
Royal Marsden Hospital NHS Trust
Samyang Biopharmaceuticals Corporation
Shanghai Junshi Bioscience Co.,Ltd.
Shanghai Xuhui District Central Hospital
SOLTI Breast Cancer Research Group
South Tees Hospitals NHS Foundation Trust
State University of New York, Buffalo
Swiss Group for Clinical Cancer Research
Technical University of Munich
The Australia and New Zealand Breast Cancer Trials Group (ANZBCTG)
The Belgian Society of Medical Oncology
The Christie NHS Foundation Trust
Translational Research in Oncology
Trans Tasman Radiation Oncology Group
Universidad Autonoma de Barcelona
Universidad Autonoma de Madrid
Universidad Complutense de Madrid
Université catholique de Louvain
University of California, San Diego
University of Campania Luigi Vanvitelli
University of Colorado, Denver
University of Las Palmas de Gran Canaria
University of Modena and Reggio Emilia
University of Naples Frederico II
University of Nice Sophia Antipolis
University of North Carolina at Chapel Hill
University of Southern Denmark
University of Texas, Galveston
University of Texas, San Antonio
Virginia Commonwealth University
Vita-Salute University of Milano. Italy
Washington University in St. Louis
Yorkshire Regional Clinical Trials Research Unit
Zhejiang Hisun Pharmaceutical Co. Ltd.
ZonMw: The Netherlands Organisation for Health Research and Development
Organization Involved with Phase 2 Indications (582)
Academic Emergency County Hospital Sibiu
Advanced Accelerator Applications
Advanced Imaging Projects, LLC
Africa Middle East Cancer Intergroup
Alliance Pour La Recherche en Cancerologie
All India Institute of Medical Sciences
American Institute for Cancer Research (AICR)
Anne Arundel Health System Research Institute
Arbeitsgemeinschaft medikamentoese Tumortherapie
Assistance Publique - Hôpitaux de Paris
Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie (ARTIC)
Associazione Italiana per la Ricerca sul Cancro
Azienda Ospedaliera Istituti Ospitalieri Cremona
Azienda Ospedaliera San Gerardo di Monza
Beijing Huanxing Cancer Hospital
Benhealth Biopharmaceutical (Shenzhen) Co., Ltd.
Berufsverband Niedergelassener Gynäkologischer Onkologen in Deutschland e.V.
Big Ten Cancer Research Consortium
Biotech Pharmaceutical Co., Ltd.
Birmingham Hematology/Oncology Associates
BriaCell Therapeutics Corporation
Burton Hospitals NHS Foundation Trust
California Breast Cancer Research Program
Canadian Institutes of Health Research (CIHR)
Cancer Centre and Institute of Oncology Warsaw
Cancer Research Group - Collaborative Group, Beirut, Lebanon.
Cancer Treatment Centers of America
Cancer Treatment Research Foundation
Catharina Hospital, Eindhoven, The Netherlands
Centre Georges Francois Leclerc
Centre Hospitalier de Luxembourg
Centre Hospitalier de Saint-Brieuc
CENTRE RENE HUGUENIN, SAINT CLOUD, FRANCE
Centro Nacional de Investigaciones Oncológicas
Centro Universitario contra el Cáncer
Clínica Hospital Dr. Ismael Vázquez Ortiz ISSSTE, Queretaro Mexico
Clinica Universidad de Navarra
Clinique Louis Cathy, Baudour, Belgium
Cliniques universitaires Saint-Luc
Commonwealth Foundation for Cancer Research
Complejo Hospitalario de Ávila
Croatian Cooperative Group for Clinical Research in Oncology
Cyclacel Pharmaceuticals, Inc.
Department of Surgery, Koja General Hospital, Jakarta, Indonesia
Developmental Therapeutics Consortium
Faculty of Medicine Universitas Indonesia - Dr Cipto Mangunkusumo Hospital
Fundacion Instituto Valenciano de Oncologia
Ganzhou City People's Hospital
Gemeinschaftspraxis Onkologie Ravensburg
Georgia Center for Oncology Research & Education
Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH
Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)
Groupe Hospitalier Public Sud Oise
Gruppo Oncologico Italiano di Ricerca Clinica
Hamilton Health Sciences Corporation
Hammoud Hospital University Medical Center
Hans and Mavis Lopater Foundation
Hellenic Cooperative Oncology Group
Hematology Oncology Consultants
HIS - Site Etterbeek - Ixelles - Belgium
Hoosier Cancer Research Network
Hospital General Regional #1 IMSS, Queretaro México
Hospital General Universitario Gregorio Marañon
Hospital Interzonal General De Agudos Eva Peron
Hospital Medico TEC100, Queretaro México
Hospital Universitario de Fuenlabrada
Hospital Universitario Infanta Leonor
Hospital Universitario Madrid Sanchinarro
Icahn School of Medicine at Mount Sinai
Immunovative Clinical Research
Infinity Pharmaceuticals, Inc.
Inflammatory Breast Cancer Network Foundation
Institut National de la Santé Et de la Recherche Médicale, France
Instituto do Cancer do Estado de São Paulo
Instituto Nacional Canerologia
Instituto Nacional de Cancer, Brazil
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Instituto National de Cancerologia, Guatemala
Institut Régional du Cancer de Montpellier
International Drug Development Institute
Istituti Ospitalieri di Cremona
Iuliu Hatieganu University of Medicine and Pharmacy
Japan Breast Cancer Research Network
Koordinierungszentren für Klinische Studien bzw. Zentren für klinische Studien
Louise & Alan Edwards Foundation
Medical Oncology Centre of Rosebank
Medical Oncology & Hematology Associates of Northern Virginia
Medical University of Bialystok
Medical University of South Carolina
Memorial Sloan-Kettering Cancer Center
Methodist Cancer Center, Houston, Texas
Michigan Cancer Research Consortium
Midwestern Regional Medical Center
Moorgreen Hospital, Southampton
Nanyang Technological University
National Autonomous University of Mexico
National Cancer Institute, Slovakia
National Center for Complementary and Integrative Health (NCCIH)
National Center for Research Resources (NCRR)
National Center of Oncology, Armenia
National Comprehensive Cancer Network
National Institute for Health Research, United Kingdom
National Institute of Oncology, Budapest
National Institutes of Health (NIH)
National University of Singapore
New Hampshire Oncology-Hematology PA
Non-State Healtcare Institution Road Clinical Hospital of Open Joint Stock Company Russian Railways
Norwegian University of Life Sciences
Oncology Therapeutic Development
Ontario Institute for Cancer Research
Organisation for Oncology and Translational Research
Panagen, Limited Liability Company
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Petrov Research Institute of Oncology
Petz, Aladar Korhaz, Onkoradiologiai Osztaly, Gyor, Hungary
Pharmaceutical Research Associates, Inc. (PRA)
Poole Hospital NHS Foundation Trust
Prof. Dr. I. Chiricuta Institute of Oncology
QuantumLeap Healthcare Collaborative
Regional Oncology Hospital, Bielsko-Biala, Poland
Russian Academy of Medical Sciences
Russian Cancer Research Center
Sana Klinikum Lichtenberg, Berlin
San Antonio Military Medical Center
Shanghai CP Guojian Pharmaceutical Co.,Ltd.
Shanghai University of Traditional Chinese Medicine
Shenzhen Geno-Immune Medical Institute
Shenzhen Hank Bioengineering Institute
Smerud Medical Research Denmark
South Eastern European Research Oncology Group
Spanish Clinical Research Network
St.-Petersburg State Budgetary Healtcare Institution City Clinical Oncological Dispensary
St. Vincent Medical Center - Los Angeles
St. Vincent's Hospital-Manhattan
Susan G. Komen Breast Cancer Foundation
Taichung Veterans General Hospital
Taipei Veteran General hospital
The Dudley Group NHS Foundation Trust
The First People's Hospital of Changzhou
The First People's Hospital of Lianyungang
The Institute of Molecular and Translational Medicine, Czech Republic
The Royal Bournemouth Hospital
The University of Texas, Dallas
Thong Chai Medical Institute Singapore
Translational Breast Cancer Research Consortium
Translational Breast Cancer Research Consortium (TBCRC)
Translational Oncology Research International
Translational Research Informatics Center, Kobe, Hyogo, Japan
Triple Negative Breast Cancer Foundation
Uniformed Services University of the Health Sciences
Universidad Nacional de Colombia
Università degli studi di Trieste
University Hospital of North Norway
University of California, Davis
University of California, Irvine
University of California, San Francisco
University of Erlangen-Nuremberg
University of Illinois at Chicago
University of Medicine and Dentistry of New Jersey
University of Roma La Sapienza
University of Southern California
University of the Witwatersrand
Western Norway Regional Health Authority
Windsor Regional Cancer Center
Organization Involved with Phase 1 Indications (153)
Acetylon Pharmaceuticals Incorporated
Advanced Imaging Research Center
Alta Bates Summit Medical Center
Association Tunisienne de lutte Contre le Cancer
Australian National University
Beijing Shenogen Biomedical Co., Ltd
BioMed Valley Discoveries, Inc
Board of Regents, State of Louisiana
Canadian Breast Cancer Research Alliance
Cancer Research Institute of Contra Costa
Dizal (Jiangsu) Pharmaceutical Co., Ltd.
DongWha Pharmaceutical Company
Eastchester Center for Cancer Care
Fundacion CRIS de Investigación para Vencer el Cáncer
Hemay Pharmaceutical PTY. LTD.
H. W. & J. Hector-Stiftung, Weinheim
ImmunoVaccine Technologies, Inc.
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Marika Iliadis Hospital of Athens
Monika-Kutzner Stiftung, Berlin
Nashville Hospital, United States
North Shore Hospital, New Zealand
Ontario Cancer Research Network
Paul Ehrlich Institute, Langen, Germany
Provectus Biopharmaceuticals, Inc.
Saint Luca International Hospital
Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.
Shanghai Pharmaceuticals Holding Co., Ltd
Sofia Perea, Director Clinical Trials Unit.
Southern California Center for Sexual Health and Survivorship Medicine
Southern Medical Day Care Centre
Suzhou Kintor Pharmaceutical Inc,
Technical University of Denmark
Terri Brodeur Breast Cancer Foundation
The START Center for Cancer Care
Organization Involved with Other Experimental Indications (73)
American Holistic Nurses Association
Associazione Umbra per la lotta Contro il Cancro
Bangabandhu Sheikh Mujib Medical University
Beijing Digital Precision Medicine Company
Big C Local Cancer Research and Care
Fundação de Amparo à Pesquisa do Estado de São Paulo
Hospital Provincial Magdalena V. de Martínez
Instituto Brasileiro de Controle do Cancer
Instituto de Biología y Medicina Experimental
National Nutrition and Food Technology Institute
Network Italiano Cure di Supporto in Oncologia
Regulatory and Clinical Research Institute Inc
South West Sydney Local Health District
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
